Peijia Medical Limited announced the completion of patient enrollment and implantation of the TaurusTrio Transcatheter Aortic Valve Replacement (TAVR) system clinical trial. TaurusTrio is a part of the licensed-in Trilogy Heart Valve System for Aortic Regurgitation (AR) from JenaValve Technology Inc. The multi-center trial utilized the TaurusTrio TAVR system to treat pure AR in 116 patients across 13 hospitals within China and is designed to assess the safety and efficacy of the TAVR system in treating patients with native symptomatic, severe AR, who were deemed to be at high or greater risk for surgical aortic valve replacement. Results of the clinical trial will be included Peijia's future submission of registration application to the National Medical Products Administration (NMPA).

In January 2022, Peijia and JenaValve entered into a technology licensing agreement wherein Peijia obtained the exclusive rights to develop and commercialize the Trilogy Heart Valve System in the Greater China region under the TaurusTrio brand.